CD47: Overcoming Tumor Evasion Through Macrophage Activation

One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping tumors avoid immune attack. CD47, known as the “don’t eat me” signal, interacts with immune cells to prevent their destruction by the body’s defense systems. However, novel therapies targeting CD47, such as anti-CD47 antibodies like MIAP301, are showing promising results in reversing this evasion strategy by activating macrophages and enhancing the body's ability to eliminate tumor cells.

CD4

7 is a transmembrane protein that is ubiquitously expressed on the surface of many cell types, including cancer cells. Its primary function is to interact with signal regulatory protein alpha (SIRPα), a receptor on macrophages and other phagocytic cells. When CD47 binds to SIRPα, it sends an inhibitory signal to the macrophage, preventing it from engulfing and destroying the cell.

This interaction is a key regulator of self-tolerance in the immune system, helping prevent the phagocytosis of healthy cells. However, cancer cells upregulate CD47 expression as a way to avoid immune destruction, effectively telling macrophages and other phagocytes, “don’t eat me.”

Tumors exploit the CD47-SIRPα axis to protect themselves from immune surveillance. By expressing high levels of CD47, they send constant inhibitory signals to macrophages, preventing the immune system from recognizing and engulfing cancer cells. This immune evasion mechanism allows tumors to grow unchecked, shielded from one of the body’s primary lines of defense.

Anti-CD47 therapies, such as MIAP301, are designed to block the interaction between CD47 on tumor cells and SIRPα on macrophages. By doing so, these antibodies allow macrophages to bypass the “don’t eat me” signal and effectively engulf and destroy tumor cells. This approach, often referred to as checkpoint blockade for macrophages, reinvigorates the innate immune response against cancer.

Anti-CD47 antibodies bind to CD47 on the surface of cancer cells, preventing it from interacting with SIRPα on macrophages. This inhibition removes the phagocytic block, allowing macrophages to recognize and engulf cancer cells. Additionally, by blocking CD47, these therapies may enhance the activity of other immune cells, such as dendritic cells and natural killer (NK) cells, further amplifying the immune response.

Key effects of anti-CD47 antibodies include:

• Restoring macrophage phagocytosis: By blocking the CD47 signal, macrophages are free to attack and digest cancer cells.


• Enhancing immune recognition: Increased phagocytosis results in greater presentation of tumor antigens, boosting adaptive immune responses.


• Synergy with other immune cells: NK cells and dendritic cells may also become more
  effective in targeting and destroying tumors.

MIAP301 is one of the most studied anti-CD47 monoclonal antibodies. It binds specifically to CD47, blocking its interaction with SIRPα and promoting macrophage activation. In preclinical studies, MIAP301 has demonstrated potent anti-tumor effects across a variety of cancer types, including leukemia, breast cancer, and solid tumors.

Anti-CD47 therapies like MIAP301 are often used in combination with other cancer treatments, such as chemotherapy or checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 antibodies. Combining these therapies can have a synergistic effect:

• Chemotherapy
  can release tumor antigens, which, in the presence of anti-CD47 treatment,
  may be more effectively presented to the immune system.


• Checkpoint inhibitors
  unleash T cells by blocking inhibitory signals like PD-1 or CTLA-4.
  Anti-CD47 therapy complements this by enhancing the macrophage response,
  leading to a coordinated attack on the tumor.

Several clinical trials are underway to test anti-CD47 antibodies like MIAP301 in cancer patients. These trials are investigating the safety and efficacy of these therapies across a wide range of cancers, from hematologic malignancies to solid tumors.

One of the most promising aspects of anti-CD47 therapy is its ability to reprogram macrophages into a more aggressive, tumor-clearing state. Typically, tumor-associated macrophages (TAMs) exist in a pro-tumor state, where they help support tumor growth and suppress immune responses. Anti-CD47 therapies help shift TAMs from this M2 phenotype (pro-tumor) to an M1 phenotype (anti-tumor), where they aggressively attack cancer cells.

While anti-CD47 therapies have shown significant promise, there are still challenges to address:

• Off-target effects:
  Because CD47 is expressed on many healthy cells, blocking this pathway can
  lead to unintended side effects, such as anemia due to the
  destruction of red blood cells. Researchers are exploring ways to mitigate
  these effects by engineering more specific antibodies.


• Tumor heterogeneity:
  Not all tumors express high levels of CD47, which may limit the
  effectiveness of anti-CD47 therapy in certain cancers.

Anti-CD47 therapies represent a new frontier in immunotherapy, with the potential to complement existing treatments and offer new hope for patients with refractory cancers. Ongoing research aims to refine these therapies, improve their specificity, and identify the cancers most likely to respond.

CD47-targeting therapies like MIAP301 offer a novel way to overcome tumor immune evasion by activating macrophages and restoring the body's natural ability to clear cancer cells. By enhancing the phagocytic activity of macrophages and working in synergy with other immunotherapies, anti-CD47 antibodies hold great promise in the treatment of multiple cancer types. As clinical trials progress, these therapies may soon become an integral part of cancer treatment strategies.

1. Majeti, R., et al., 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138(2), pp.286-299.


2. Willingham, S.B., et al., 2012. The CD47–SIRPα interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences, 109(17), pp.6662-6667.


3. Chao, M.P., et al., 2010. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142(5), pp.699-713.


4. Weiskopf, K., et al., 2016. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation, 126(7), pp.2610-2620.


5. Advani, R., et al., 2018. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. New England Journal of Medicine, 379(18), pp.1711-1721.


6. Sikic, B.I., et al., 2019. First-in-human phase 1 trial of the anti-CD47 antibody Hu5F9-G4 in patients with solid tumors. Annals of Oncology, 30(5), pp.1003-1010.


7. Zhao, X.W., et al., 2011. CD47–SIRPα interactions are involved in tumor immune evasion by inhibiting neutrophil-mediated destruction of antibody-opsonized tumor cells. Journal of Immunology, 186(7), pp.4223-4231.


8. Liu, J., et al., 2015. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One, 10(9), p.e0137345.